Artica Therapeutics

Artica Therapeutics develops medicines for inflammatory and autoimmune diseases based on covalent binding technology. The biotech company has over a decade of experience with this approach, has in-house assay capabilities, and selects targets for drug development. Artica has a track record in developing approved covalent medicines. The €12 million investment will be used to prepare candidate drugs for clinical validation studies.